MD Anderson’s Lung Cancer Research Program is striving to change those statistics. We’re working hard to speed innovative therapies to the clinic through an array of clinical trials funded by the U.S. Department of Defense and philanthropy.
One of them, featured in this issue, is aptly named BATTLE (Biomarker- Integrated Approaches of Targeted Therapy for Lung Cancer Elimination) as investigators continue their fight to beat this deadly disease. BATTLE is open to patients with late-stage non-small cell lung cancer. Its goal is to establish molecular-based, personalized targeted therapy by first examining the biomarker profiles of individual tumors, then assigning therapies that offer the best benefits based on those characteristics.
Your generosity, dedication and support are more important than ever before. Together, we can make a difference for cancer patients everywhere.